Proteomics comparison of the sera from multiple sclerosis patients and neuromyelitis optica patients.

This study aimed to identify the proteins that are differentially expressed in sera of multiple sclerosis (MS) patients, neuromyelitis optica (NMO) patients, and normal controls by using a two-dimensional gel electrophoresis (2-DE) assay. Serum samples were collected from the 3 groups, and total proteins were isolated and quantified by using the Bradford assay. The 2-DE and silver staining were carried out, and the Image Master 2D Platinum 5.0 software was used to analyze the images. Differentially expressed protein spots were removed from the gel and digested by enzymolysis and high-definition tandem mass spectrometry, and the MASCOT online software was applied to identify the proteins. Three differentially expressed proteins were identified: immunoglobulin (Ig) lambda chain, keratin 83, and haptoglobin (Hp2); the Ig lambda chain was only found in MS patients. The expression of keratin 83 was significantly elevated in the MS group compared to the normal control or NMO groups. The expression of Hp2 in the NMO group was elevated by more than 2-fold compared to the normal control or MS groups. In summary, a variety of proteins were found to be differentially expressed in the serum between MS, NMO, and normal subjects using 2-DE: Ig lambda, Hp2, and keratin 83 were identified as potential diagnostic markers or treatment targets for MS or NMO.

[1]  Fumio Nomura,et al.  Serum levels of complement C4 fragments correlate with disease activity in multiple sclerosis: Proteomic analysis , 2010, Journal of Neuroimmunology.

[2]  M. Milazzo,et al.  Protein expression profiles in pediatric multiple sclerosis: potential biomarkers , 2009, Multiple sclerosis.

[3]  I. Kacskovics,et al.  Immunoglobulins, antibody repertoire and B cell development. , 2009, Developmental and comparative immunology.

[4]  A. Argyriou,et al.  Neuromyelitis optica: a distinct demyelinating disease of the central nervous system , 2008, Acta neurologica Scandinavica.

[5]  M. Lana-Peixoto.  Devic's neuromyelitis optica: a critical review. , 2008, Arquivos de neuro-psiquiatria.

[6]  D. Arnold,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.

[7]  B. Giometto,et al.  Revised diagnostic criteria for neuromyelitis optica (NMO) , 2007, Journal of Neurology.

[8]  P. Vermersch,et al.  Immunosuppressive therapy is more effective than interferon in neuromyelitis optica , 2007, Multiple sclerosis.

[9]  Ichiro Nakashima,et al.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.

[10]  K. Blennow,et al.  Validation of a prefractionation method followed by two-dimensional electrophoresis – Applied to cerebrospinal fluid proteins from frontotemporal dementia patients , 2004, Proteome Science.

[11]  R. Bergamaschi,et al.  Oligoclonal bands in Devic’s neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations , 2004, Multiple sclerosis.

[12]  K. Blennow,et al.  Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. , 2002, Brain research. Molecular brain research.

[13]  J. Noseworthy.  Progress in determining the causes and treatment of multiple sclerosis , 1999, Nature.

[14]  S. Hauser,et al.  Identification of autoantibodies associated with myelin damage in multiple sclerosis , 1999, Nature Medicine.

[15]  M. O’Bryan,et al.  Haptoglobin is a Sertoli cell product in the rat seminiferous epithelium: its purification and regulation. , 1997, Journal of andrology.

[16]  J. Delanghe,et al.  Biological and clinical significance of haptoglobin polymorphism in humans. , 1996, Clinical chemistry.

[17]  W. Waldhäusl,et al.  Haptoglobin phenotyping by newly developed monoclonal antibodies. Demonstration of haptoglobin uptake into peripheral blood neutrophils and monocytes. , 1996, Journal of immunology.

[18]  C. Lucchinetti.  Pathological heterogeneity of idiopathic central nervous system inflammatory demyelinating disorders. , 2008, Current topics in microbiology and immunology.

[19]  A. Verkman,et al.  The Journal of Experimental Medicine CORRESPONDENCE , 2005 .